Trince

Ottergemsesteenweg-Zuid 731

9000 Gent

BE

Trince

Foundation date

17/09/2021

Sector

#Supplier & Engineering

Subsector

Trince, a spin-off company from UGent is dedicated to delivering molecules into cells, both in vitro and ex vivo. Its LumiPore transfection platform combines laser exposure and nanoparticles to transiently permeabilize cell membranes. It can be used to deliver a wide variety of effector molecules into virtually any cell type, including hard-to-transfect cells. The high-throughput technology ensures efficient and gentle transfection, maximizing the therapeutic quality of the final cell product.

Upcoming events

Latest news

  • argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • Galapagos appoints Simon Sturge to its Board of Directors

    Tuesday September 19th 2023

  • 13th Investment for HERAN Partners: Broken String Biosciences (UK)

    Tuesday September 19th 2023